Cediranib for metastatic alveolar soft part sarcoma

Journal of Clinical Oncology

Volumn 31, Issue 18, 2013, Pages 2296-2302

  Kummar, Shivaani ^a   Allen, Deborah ^a   Monks, Anne ^b   Polley, Eric C ^a   Hose, Curtis D ^b   Ivy, S Percy ^a   Turkbey, Ismail B ^a   Lawrence, Scott ^b   Kinders, Robert J ^b   Choyke, Peter ^a   Simon, Richard ^a   Steinberg, Seth M ^a   Doroshow, James H ^a   Helman, Lee ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ALVEOLAR SOFT PART SARCOMA; ANGIOGENESIS; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER PAIN; CLINICAL ARTICLE; CONFUSION; DIARRHEA; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; GENE EXPRESSION PROFILING; HAND FOOT SYNDROME; HEADACHE; HEARTBURN; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOTHYROIDISM; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MICROARRAY ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; UNDERWEIGHT; VOMITING; CHEMICALLY INDUCED DISORDER; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANOREXIA; ANTINEOPLASTIC AGENTS; DIARRHEA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSPECTIVE STUDIES; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, ALVEOLAR SOFT PART; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882955940     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.4288     Document Type: Article

References (25)

1. Zarrin-Khameh N, Kaye KS: Alveolar soft part sarcoma. Arch Pathol Lab Med 131:488-491, 2007
2. Lieberman PH, Brennan MF, Kimmel M, et al: Alveolar soft-part sarcoma: A clinico-pathologic study of half a century. Cancer 63:1-13, 1989
3. Portera CA Jr, Ho V, Patel SR, et al: Alveolar soft part sarcoma: Clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91:585-591, 2001
4. Reichardt P, Lindner T, Pink D, et al: Chemotherapy in alveolar soft part sarcomas: What do we know? Eur J Cancer 39:1511-1516, 2003
5. Ladanyi M, Lui MY, Antonescu CR, et al: The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20:48-57, 2001
6. Argani P, Antonescu CR, Illei PB, et al: Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159:179-192, 2001
7. Tsuda M, Davis IJ, Argani P, et al: TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67:919-929, 2007
8. Lorigan JG, O’Keeffe FN, Evans HL, et al: The radiologic manifestations of alveolar soft-part sarcoma. AJR Am J Roentgenol 153:335-339, 1989
9. Stockwin LH, Vistica DT, Kenney S, et al: Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 9:22, 2009
10. Lazar AJ, Das P, Tuvin D, et al: Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 13:7314-7321, 2007
11. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005
12. Smith NR, James NH, Oakley I, et al: Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6:2198-2208, 2007
13. Fox E, Aplenc R, Bagatell R, et al: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28:5174-5181, 2010
14. Gardner K, Judson I, Leahy M, et al: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 27:541s, 2009 (suppl 15S; abstr 10523)
15. National Cancer Institute: Common Terminology Criteria for Adverse Events version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
17. Kummar S, Gutierrez ME, Chen A, et al: Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 47:997-1005, 2011
18. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007
19. Matulonis UA, Berlin S, Ivy P, et al: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601-5606, 2009
20. Mulders P, Hawkins R, Nathan P, et al: Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study. Eur J Cancer 48:527-537, 2012
21. Wagner AJ, Goldberg JM, Dubois SG, et al: Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. Cancer 118:5894-5902, 2012
22. Gherardi E, Birchmeier W, Birchmeier C, et al: Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12:89-103, 2012
23. Sennino B, Ishiguro-Oonuma T, Wei Y, et al: Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270-287, 2012
24. Chen W, Li Z, Bai L, et al: NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci 16:1172-1185, 2011
25. Stacchiotti S, Negri T, Zaffaroni N, et al: Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect. Ann Oncol 22:1682-1690, 2011